Markets
Merck HIV Trial Data at AIDS 2026: What Traders Need to Know About MRK Stock
Merck is set to present pivotal HIV treatment trial data at the international AIDS 2026 conference, a binary catalyst event that could reprice MRK shares and ripple across the broader biopharma sector. Here is what traders and investors need to understand before the data drops.